Publications by authors named "Joseph Balint"

Claim this Profile
D
Dual-Antigen COVID-19 Vaccine Subcutaneous Prime Delivery With Oral Boosts Protects NHP Against SARS-CoV-2 Challenge.
Elizabeth Gabitzsch, Jeffrey T Safrit, Mohit Verma, Adrian Rice, Peter Sieling, Joseph Balint

Front Immunol· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intranasal plus subcutaneous prime vaccination with a dual antigen COVID-19 vaccine elicits T-cell and antibody responses in mice.
Adrian Rice, Mohit Verma, Annie Shin, Lise Zakin, Peter Sieling, Joseph Balint

Sci Rep· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adenoviral vector-based vaccine is fully protective against lethal Lassa fever challenge in Hartley guinea pigs.
Junki Maruyama, Elizabeth J Mateer, John T Manning, Rachel Sattler, Alexey V Seregin, Joseph P Balint

Vaccine· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The generation and analyses of a novel combination of recombinant adenovirus vaccines targeting three tumor antigens as an immunotherapeutic.
Elizabeth S Gabitzsch, Kwong Yok Tsang, Claudia Palena, Justin M David, Massimo Fantini, Joseph P Balint

Oncotarget· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Extended evaluation of a phase 1/2 trial on dosing, safety, immunogenicity, and overall survival after immunizations with an advanced-generation Ad5 [E1-, E2b-]-CEA(6D) vaccine in late-stage colorectal cancer.
Joseph P Balint, Elizabeth S Gabitzsch, Adrian Rice, Yvette Latchman, Younong Xu

Cancer Immunol Immunother· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel adenoviral vector induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients.
Michael A Morse, Arvind Chaudhry, Elizabeth S Gabitzsch, Amy C Hobeika, Takuya Osada, Joseph P Balint

Cancer Immunol Immunother· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Induction and comparison of SIV immunity in Ad5 naïve and Ad5 immune non-human primates using an Ad5 [E1-, E2b-] based vaccine.
Elizabeth S Gabitzsch, Younong Xu, Joseph P Balint, Stephanie Balcaitis, Brigitte Sanders-Beer

Vaccine· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevention of influenza virus shedding and protection from lethal H1N1 challenge using a consensus 2009 H1N1 HA and NA adenovirus vector vaccine.
Frank R Jones, Elizabeth S Gabitzsch, Younong Xu, Joseph P Balint, Viktoriya Borisevich

Vaccine· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-tumor immunotherapy despite immunity to adenovirus using a novel adenoviral vector Ad5 [E1-, E2b-]-CEA.
Elizabeth S Gabitzsch, Younong Xu, Joseph P Balint, Zachary C Hartman, H Kim Lyerly

Cancer Immunol Immunother· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel Adenovirus type 5 vaccine platform induces cellular immunity against HIV-1 Gag, Pol, Nef despite the presence of Ad5 immunity.
Elizabeth S Gabitzsch, Younong Xu, Lois H Yoshida, Joseph Balint, Andrea Amalfitano

Vaccine· October 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A preliminary and comparative evaluation of a novel Ad5 [E1-, E2b-] recombinant-based vaccine used to induce cell mediated immune responses.
Elizabeth S Gabitzsch, Younong Xu, Lois H Yoshida, Joseph Balint, Richard B Gayle

Immunol Lett· January 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis